Abstract 344P
Background
Acute myeloid leukemia (AML) is primarily treated with chemotherapy. Patients who are unable to undergo intensive chemotherapy may receive substitutional therapy, such as venetoclax, a BCL-2 inhibitor that showed promising results by combining it with azacitidine. Recent clinical trials have demonstrated the effectiveness of venetoclax-azacitidine in AML treatment. Thus, this review aims to compare the efficacy and serious adverse events (SAE) of venetoclax-azacitidine vs azacitidine used alone in patients diagnosed with AML.
Methods
Authors independently extracted studies from 2013 to 2023 using databases such as Pubmed, Pubmed Central, Springer Link, ScienceDirect, Medrxiv, and Google Scholar. Keywords used were "venetoclax" AND "azacitidine" AND "acute myeloid leukemia". We assessed the quality of each study using the modified JADAD scale with funnel plot to assess publication bias and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) to determine the quality of this review. A pooled analysis of OS and EFS hazard ratio (HR) and SAE ratio between the two groups were done to establish correlation.
Results
We included 7 records, representing 3 trials, involving 1499 patients. 2 studies were of low quality, with the other 3 studies and the other 2 studies were of moderate and high quality respectively. This review showed moderate quality based on GRADE with minimum publication bias. The use of combining venetoclax and azacitidine did improve OS (HR = 0.58; 95% CI 0.51-0.65 ; P < 0.001) and EFS (HR = 0.50 ; 95% CI 0.30-0.84 ; P = 0.008), but have higher SAE (OR = 1.81 ; 95% CI 1.29-2.52 ; P = 0.0005) compared to azacitidine alone.
Conclusions
This review revealed that venetoclax-azacitidine demonstrated enhanced OS and EFS outcomes, with higher serious adverse events (SAE) when compared to azacitidine in AML patients. This concludes that venetoclax-azacitidine holds promise as a potential treatment for AML patients although its safety still needs to be monitored closely. Further studies needed to observe the administration of venetoclax-azacitidine vs azacitidine AML in different subgroups, more importantly the cytogenetic risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract